JNJ Stock Summary and Trading Ideas (Johnson & Johnson | NYSE:JNJ)

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

Johnson & Johnson trades on the NYSE stock market under the symbol JNJ.

As of February 17, 2026, JNJ stock price declined to $243.33 with 9,600,976 million shares trading.

JNJ has a beta of 0.15, meaning it tends to be less sensitive to market movements. JNJ has a correlation of 0.02 to the broad based SPY ETF.

JNJ has a market cap of $585.94 billion. This is considered a Mega Cap stock.

Last quarter Johnson & Johnson reported $25 billion in Revenue and $2.46 earnings per share. This beat revenue expectation by $414 million and missed earnings estimates by -$.01.

In the last 3 years, JNJ traded as high as $246.35 and as low as $140.68.

The top ETF exchange traded funds that JNJ belongs to (by Net Assets): VTI, VOO, IVV, SPY, VTV.

JNJ has outperformed the market in the last year with a price return of +58.0% while the SPY ETF gained +13.2%. JNJ has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +25.3% and +7.1%, respectively, while the SPY returned +1.9% and -1.3%, respectively.

JNJ support price is $240.84 and resistance is $246.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JNJ shares will trade within this expected range on the day.